Anindita Chakrabarty
Greater Noida, UP, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Heat Shock Protein Inhibitor Tanespimycin (17AAG) Suppresses SARS-CoV-2 Main Protease Activity and Is More Potent Than Clinically Approved Antiviral Nirmatrelvir.
Journal: Chembiochem : a European journal of chemical biology
Published: January 25, 2026
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity.
Journal: Journal of visualized experiments : JoVE
Published: November 03, 2025
Mapping the Progression of Therapy-Induced Senescence to Therapy Tolerance: An Evolutionarily Conserved Mechanism for Optimizing Cancer Treatment with Senotherapeutics.
Journal: ACS pharmacology & translational science
Published: May 23, 2025
Repurposing resveratrol for redox-mediated inhibition of MTH1 in breast cancer.
Journal: Scientific reports
Published: April 29, 2025
O6-Alkylguanine-DNA Alkyltransferase Maintains Genome Integrity by Forming DNA-Protein Cross-Links during Inflammation-Associated Peroxynitrite-Mediated DNA Damage.
Journal: Chemical research in toxicology
Published: October 21, 2024
Thymoquinone, artemisinin, and thymol attenuate proliferation of lung cancer cells as Sphingosine kinase 1 inhibitors.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: May 03, 2024
Editorial: Resistance to endocrine therapies in cancer, volume II.
Journal: Frontiers in endocrinology
Published: April 08, 2024
Targeting prostate cancer via therapeutic targeting of PIM-1 kinase by Naringenin and Quercetin.
Journal: International journal of biological macromolecules
Published: March 24, 2024
Design, synthesis, molecular docking and anti-proliferative activity of novel phenothiazine containing imidazo[1,2-a]pyridine derivatives against MARK4 protein.
Journal: RSC medicinal chemistry
Published: January 23, 2024
Exploring MTH1 inhibitory potential of Thymoquinone and Baicalin for therapeutic targeting of breast cancer.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: December 18, 2023
Opposing Interplay between Nuclear Factor Erythroid 2-Related Factor 2 and Forkhead BoxO 1/3 is Responsible for Sepantronium Bromide's Poor Efficacy and Resistance in Cancer cells: Opportunity for Combination Therapy in Triple Negative Breast Cancer.
Journal: ACS pharmacology & translational science
Published: October 11, 2023
Last Updated: 09/26/2026